Compare NLY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NLY | EXAS |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 19.3B |
| IPO Year | 1997 | N/A |
| Metric | NLY | EXAS |
|---|---|---|
| Price | $22.97 | $102.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | $23.55 | ★ $84.27 |
| AVG Volume (30 Days) | ★ 9.1M | 2.4M |
| Earning Date | 01-28-2026 | 02-18-2026 |
| Dividend Yield | ★ 12.17% | N/A |
| EPS Growth | ★ 80.25 | N/A |
| EPS | ★ 2.92 | N/A |
| Revenue | $2,304,722,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $166.06 | $19.40 |
| Revenue Next Year | $9.61 | $13.54 |
| P/E Ratio | $7.88 | ★ N/A |
| Revenue Growth | ★ 84.69 | 14.47 |
| 52 Week Low | $16.60 | $38.81 |
| 52 Week High | $24.52 | $102.66 |
| Indicator | NLY | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 74.75 |
| Support Level | $23.56 | $102.12 |
| Resistance Level | $24.52 | $102.59 |
| Average True Range (ATR) | 0.49 | 0.31 |
| MACD | -0.06 | -0.40 |
| Stochastic Oscillator | 6.49 | 63.83 |
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.